Emiel Rutgers was ‘tailoring’ his therapies long before the term was popularised. He pioneered breast conservation and neo-adjuvant chemotherapy in the Netherlands against opposition, but was also an advocate, just as controversially, of complete mastectomy of healthy breasts as an option for women at high risk. To be effective in this genomic era, cancer surgeons must keep abreast of the science, he argues.
Leave a Reply